Every peptide researcher eventually encounters the same frustrating scenario: a protocol that works brilliantly on paper produces inconsistent results in practice. The compound degrades before it reaches target tissues, or plasma concentrations spike and crash unpredictably. More often than not, the missing variable is half-life — the single pharmacokinetic parameter that dictates when, how often, and in what form a peptide should be administered.

Half-life is not merely an academic curiosity. It is the governing clock of peptide pharmacology, and understanding it separates informed protocols from guesswork.

What Half-Life Actually Means in Peptide Science

The biological half-life of a peptide (sometimes written as t1/2) is the time required for its plasma concentration to fall by exactly 50%. After one half-life, half the original amount remains. After two half-lives, one quarter. After five half-lives, less than 3.2% of the initial dose is circulating — a threshold pharmacologists treat as effective elimination.

This exponential decay is not unique to peptides, but peptides present special challenges. Unlike small-molecule drugs that can survive the acidic environment of the stomach and the enzymatic gauntlet of first-pass hepatic metabolism, most peptides are rapidly degraded by proteases in the blood, liver, and kidneys. A native, unmodified peptide injected into the bloodstream may have a half-life measured in single-digit minutes.

That biological fragility is exactly why half-life data matters so much for protocol design. A two-minute half-life demands a fundamentally different administration strategy than a 120-hour one.

The Factors That Determine Peptide Half-Life

Several interconnected mechanisms control how quickly a peptide is cleared from circulation:

Molecular Weight and Chain Length

Smaller peptides (under approximately 5 kDa) are filtered rapidly by the kidneys through glomerular filtration. Larger peptides and those conjugated to carrier molecules avoid this route, extending their presence in circulation substantially.

Protease Susceptibility

Endopeptidases and exopeptidases in plasma, tissue surfaces, and intracellular compartments cleave peptide bonds with remarkable efficiency. The amino acid sequence itself determines vulnerability — certain motifs are recognized and cut within seconds of exposure to blood.

Receptor Binding Kinetics

Peptides with high receptor affinity and slow dissociation rates effectively "hide" from degradation while bound. This receptor-mediated protection can dramatically extend the functional half-life beyond what plasma clearance measurements suggest.

Structural Modifications

Modern peptide engineering has developed several strategies to extend half-life: PEGylation (attachment of polyethylene glycol chains), lipidation (fatty acid conjugation that enables albumin binding), cyclization (ring structures that resist enzymatic cleavage), and non-natural amino acid substitution (replacement of L-amino acids with D-forms or other analogues that proteases cannot recognize).

Route of Administration

Subcutaneous injection creates a depot effect where the peptide slowly absorbs from the injection site into circulation, producing a different pharmacokinetic profile compared to intravenous administration. Intranasal delivery, oral administration with protective excipients, and transdermal approaches each introduce their own absorption kinetics that interact with the peptide's intrinsic half-life.

Peptide Half-Life Comparison Table

The following table summarizes approximate half-life values for research peptides commonly discussed in the scientific literature. These figures derive from published pharmacokinetic studies and should be considered reference ranges rather than absolute values, as individual variation, formulation differences, and assay methods can influence measurements.

Peptide	Approximate Half-Life	Category	Key Pharmacokinetic Notes
BPC-157	~4 hours (estimated)	Tissue repair	Limited formal PK data; stable in gastric acid, which is unusual for peptides. Oral and injectable routes both studied.
TB-500 (Thymosin Beta-4)	~2 hours	Tissue repair	Rapid distribution to tissues; effects may persist well beyond plasma clearance due to intracellular activity.
Tirzepatide	~5 days (120 hours)	GLP-1/GIP dual agonist	C20 fatty diacid enables albumin binding; engineered for once-weekly dosing. One of the longest half-lives among therapeutic peptides.
Semaglutide	~7 days (168 hours)	GLP-1 agonist	Fatty acid acylation + amino acid substitutions prevent DPP-4 degradation. Once-weekly injectable; daily oral form uses absorption enhancer (SNAC).
CJC-1295 (with DAC)	~6–8 days	GHRH analogue	Drug Affinity Complex (DAC) binds albumin covalently, dramatically extending half-life from minutes to days.
CJC-1295 (no DAC / Mod GRF 1-29)	~30 minutes	GHRH analogue	Without DAC, clearance is rapid. Typically combined with a GHRP for pulsatile GH release.
Ipamorelin	~2 hours	GHRP / Ghrelin mimetic	Selective GH release with minimal effect on cortisol or prolactin. Short half-life suits pulsatile dosing.
GHRP-6	~15–60 minutes	GHRP / Ghrelin mimetic	Very short-acting; strong GH pulse but also stimulates appetite via ghrelin receptor activation.
GHRP-2	~25–60 minutes	GHRP / Ghrelin mimetic	Slightly longer-acting than GHRP-6 with less appetite stimulation. Dose-dependent GH response.
Hexarelin	~70 minutes	GHRP / Ghrelin mimetic	Potent GH release but subject to tachyphylaxis (reduced response) with continuous use.
PT-141 (Bremelanotide)	~2.5 hours	MC receptor agonist	Metabolite active at MC receptors; effects can last 6–12 hours despite relatively short plasma half-life.
Melanotan II	~1 hour	MC receptor agonist	Non-selective melanocortin agonist; rapid clearance but melanogenesis effects accumulate over multiple doses.
GHK-Cu	~Minutes	Copper peptide	Tripeptide cleared extremely rapidly from plasma. Primarily used topically where skin depot effects are more relevant.
Epithalon (Epitalon)	~30 minutes (estimated)	Telomerase activator	Short tetrapeptide; limited published PK. Effects attributed to telomerase activation may persist beyond clearance.
Selank	~1–3 minutes (native)	Anxiolytic peptide	Extremely rapid degradation; modified analogues under investigation for extended duration.
Semax	~2–3 minutes (native)	Nootropic peptide	Intranasal administration extends functional duration despite very short plasma half-life.
AOD-9604	~30–60 minutes	GH fragment	C-terminal fragment of growth hormone; lipolytic activity without GH receptor activation.
Retatrutide	~6 days	GLP-1/GIP/Glucagon triple agonist	Fatty acid conjugation enables weekly dosing; triple receptor engagement is unique in this class.
Liraglutide	~13 hours	GLP-1 agonist	Palmitic acid acylation promotes albumin binding. Once-daily dosing; shorter half-life than semaglutide.

Why a Few Hours vs. a Few Days Changes Everything

The practical implications of half-life differences are enormous. Consider two peptides from the table above: ipamorelin (approximately 2 hours) and tirzepatide (approximately 5 days). These are not just different numbers — they represent fundamentally different pharmacological paradigms.

Ipamorelin's short half-life means it produces a sharp, defined pulse of activity followed by rapid clearance. This is actually desirable for growth hormone secretagogues, because the pituitary naturally releases GH in pulsatile bursts. A long-acting GH secretagogue would produce continuous stimulation, potentially leading to receptor desensitization and paradoxically less total GH output.

Tirzepatide's extended half-life, by contrast, is engineered for sustained receptor engagement. GLP-1 and GIP receptors benefit from continuous activation for metabolic effects, and the convenience of once-weekly dosing dramatically improves adherence — a critical factor in protocols lasting months or years.

Calculating Steady State: When Repeated Doses Overlap

When a peptide is administered at regular intervals, each new dose adds to the residual amount from previous doses. Eventually, the rate of elimination equals the rate of administration, producing a steady-state concentration. This typically occurs after approximately 4 to 5 half-lives of consistent dosing.

For a peptide with a 5-day half-life, steady state is not reached until roughly 20 to 25 days of weekly dosing. During this loading phase, plasma levels are progressively climbing. Researchers who evaluate a protocol after just one or two doses may be assessing a compound that has not yet reached its pharmacologically intended concentration.

For short half-life peptides administered multiple times daily, steady state arrives much sooner — within a day or two. But the trade-off is a "sawtooth" pharmacokinetic profile with pronounced peaks and troughs between doses.

The Gap Between Plasma Half-Life and Duration of Effect<...